Login / Signup

Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.

Mahesh RaundhalShrestha GhoshSamuel A MyersMichael S CuocoMeromit SingerSteven A CarrSushrut S WaikarJoseph V BonventreJerome RitzRichard M StoneDavid P SteensmaAviv RegevLaurie H Glimcher
Published in: Nature immunology (2021)
Patients with myelodysplastic syndromes (MDSs) display severe anemia but the mechanisms underlying this phenotype are incompletely understood. Right open-reading-frame kinase 2 (RIOK2) encodes a protein kinase located at 5q15, a region frequently lost in patients with MDS del(5q). Here we show that hematopoietic cell-specific haploinsufficient deletion of Riok2 (Riok2f/+Vav1cre) led to reduced erythroid precursor frequency leading to anemia. Proteomic analysis of Riok2f/+Vav1cre erythroid precursors suggested immune system activation, and transcriptomic analysis revealed an increase in p53-dependent interleukin (IL)-22 in Riok2f/+Vav1cre CD4+ T cells (TH22). Further, we discovered that the IL-22 receptor, IL-22RA1, was unexpectedly present on erythroid precursors. Blockade of IL-22 signaling alleviated anemia not only in Riok2f/+Vav1cre mice but also in wild-type mice. Serum concentrations of IL-22 were increased in the subset of patients with del(5q) MDS as well as patients with anemia secondary to chronic kidney disease. This work reveals a possible therapeutic opportunity for reversing many stress-induced anemias by targeting IL-22 signaling.
Keyphrases
  • chronic kidney disease
  • stress induced
  • end stage renal disease
  • wild type
  • iron deficiency
  • stem cells
  • type diabetes
  • bone marrow
  • mesenchymal stem cells
  • cell therapy
  • peritoneal dialysis
  • early onset
  • insulin resistance